Case ID: M10-038L

Published: 2023-04-14 10:34:20

Last Updated: 1681917228


Michael Sierks
Shanta Boddapati
Srinath Kasturirangan

Technology categories

Life Science (All LS Techs)Neurodegenerative Disease TechnologiesNon-Cancer TherapeuticsPharmaceuticals

Technology keywords


Licensing Contacts

Jovan Heusser
Director of Licensing and Business Development
[email protected]

Bi-specific Antibodies as a Therapeutic for Alzheimer’s Disease

Alzheimer’s disease (AD) is one of the most prominent and feared neurodegenerative diseases associated with aging. A hallmark of this disease is the formation of extra-cellular amyloid plaques in the brain. The principle component of these extracellular plaques is amyloid-ß protein (Aß). Though the mechanisms underlying Alzheimer’s disease pathology remain controversial, accumulation and deposition of Aß appears to play a critical role in the pathogenesis of AD. 

Amyloid-ß protein is formed through cleavage of amyloid precursor protein (APP) by beta-secretase. Alternatively, cleavage of APP by alpha-secretase, results in a non-pathogenic outcome and no accumulation of Aß. A viable therapeutic approach therefore might be to facilitate the clearance and reduction of Aß by targeting these pathways.


Researchers at Arizona State University have successfully synthesized a bi-functional recombinant antibody as a treatment for AD. The bi-specific construct is composed of two single chain antibody fragments (scFV): one that blocks beta-secretase activity by binding to the substrate APP (but not Aß), and a second that promotes alpha-secretase activity by specifically cleaving at the alpha-secretase site of Aß or APP.


This invention may have significant potential as an effective therapeutic for AD.


Potential Applications

  • Antibody to treat Alzheimer’s Disease

Benefits and Advantages

  • Non-inflammatory: Antibody fragment is derived from a humanized library
  • Specific: The antibody fragment binds to amyloid precursor protein without cross-reacting with amyloid-ß protein
  • Bifunctional: The antibody fragment blocks formation of Aß and promotes non-pathogenic (alpha-secretase mediated) cleavage of amyloid precursor protein


For more information about the inventor(s) and their research, please see
Dr. Sierks' directory webpage
Dr. Sierks' laboratory webpage